These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9205018)

  • 1. Effects of amiodarone on the circadian pattern of sudden cardiac death (Department of Veterans Affairs Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy).
    Behrens S; Ney G; Fisher SG; Fletcher RD; Franz MR; Singh SN
    Am J Cardiol; 1997 Jul; 80(1):45-8. PubMed ID: 9205018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy.
    Singh SN; Fletcher RD
    Am J Cardiol; 1999 Nov; 84(9A):103R-108R. PubMed ID: 10568668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.
    Singh SN; Fletcher RD; Fisher SG; Singh BN; Lewis HD; Deedwania PC; Massie BM; Colling C; Lazzeri D
    N Engl J Med; 1995 Jul; 333(2):77-82. PubMed ID: 7539890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amiodarone in congestive heart failure.
    Singh S
    Int J Clin Pract; 1998 Sep; 52(6):432-5. PubMed ID: 9894384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
    G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congestive heart failure: survival trial of antiarrhythmic therapy (CHF STAT). The CHF STAT Investigators.
    Singh S; Fletcher RD; Fisher S; Deedwania P; Lewis D; Massie B; Singh B; Colling CL
    Control Clin Trials; 1992 Oct; 13(5):339-50. PubMed ID: 1385036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
    Packer DL; Prutkin JM; Hellkamp AS; Mitchell LB; Bernstein RC; Wood F; Boehmer JP; Carlson MD; Frantz RP; McNulty SE; Rogers JG; Anderson J; Johnson GW; Walsh MN; Poole JE; Mark DB; Lee KL; Bardy GH
    Circulation; 2009 Dec; 120(22):2170-6. PubMed ID: 19917887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
    Bardy GH; Lee KL; Mark DB; Poole JE; Packer DL; Boineau R; Domanski M; Troutman C; Anderson J; Johnson G; McNulty SE; Clapp-Channing N; Davidson-Ray LD; Fraulo ES; Fishbein DP; Luceri RM; Ip JH;
    N Engl J Med; 2005 Jan; 352(3):225-37. PubMed ID: 15659722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators.
    Deedwania PC; Singh BN; Ellenbogen K; Fisher S; Fletcher R; Singh SN
    Circulation; 1998 Dec; 98(23):2574-9. PubMed ID: 9843465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose amiodarone in severe chronic heart failure.
    Biswas A; Dey SK; Banerjee AK; Roy S; Biswas PK; Chowdhury GK; Khan AK; Mitra KK; Chatterjee SS; Maity AK
    Indian Heart J; 1996; 48(4):361-4. PubMed ID: 8908821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials.
    Farré J; Romero J; Rubio JM; Ayala R; Castro-Dorticós J
    Am J Cardiol; 1999 Mar; 83(5B):55D-63D. PubMed ID: 10089841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heart failure and treatment of ventricular arrhythmias].
    Junga G; Duru F; Candinas R
    Praxis (Bern 1994); 1999 Feb; 88(6):215-22. PubMed ID: 10081339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators.
    Singh SN; Fisher SG; Carson PE; Fletcher RD
    J Am Coll Cardiol; 1998 Oct; 32(4):942-7. PubMed ID: 9768715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
    Au-Yeung WT; Reinhall PG; Poole JE; Anderson J; Johnson G; Fletcher RD; Moore HJ; Mark DB; Lee KL; Bardy GH
    Heart Rhythm; 2015 Oct; 12(10):2058-66. PubMed ID: 26096609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.
    Lancet; 1997 Nov; 350(9089):1417-24. PubMed ID: 9371164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.
    Cecchi F; Olivotto I; Montereggi A; Squillatini G; Dolara A; Maron BJ
    Heart; 1998 Apr; 79(4):331-6. PubMed ID: 9616338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.